Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Patients
Status:
Active, not recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate the long-term safety and tolerability of
filgotinib (formerly GLPG0634) for the treatment of rheumatoid arthritis.
Participants will be enrolled in this open-label long-term follow-up study after they have
completed one of the two core studies, GLPG0634-CL-203 (DARWIN1) or GLPG0634-CL-204
(DARWIN2), and will be evaluated for any side effects that may occur (long-term safety and
tolerability) when taking filgotinib. During the course of the study, participants will also
be examined for long-term effects of filgotinib administration on disease activity
(efficacy), subjects' disability, fatigue, and quality of life.